Views & Analysis Could AI create a brave new world of pharma R&D? Barely a week goes by without one big pharma or biotech announcing that it is using AI to develop new medicines.
Partner Content Partner Content 3rd Annual AI-ML Drug Discovery & Development Summit Discover Case Studies of Machine Learning in Action
Events Partner Content 13th Annual Pharma Resource Planning and Portfolio Managemen... Prioritizing Projects with Tools, Data, and Governance
Partner Content Partner Content Understanding the evolving CAR-T market In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy.
News BioNTech and Vir prepare mega-IPOs after flurry of launches Two of the largest-ever biotech initial public offerings (IPOs) are scheduled to go ahead in the coming week, after a flurry of smaller stock market launches last week.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.